Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Reason given: The study was stopped due to exhaustion of funding. No additional financial support could be obtained to continue study operations as planned.
Key facts
- Where
- Atlanta, Aurora, Boston, Buffalo, Charlotte, Chicago, Cleveland, Columbus, Duarte, Miami, Nashville, New York, San Francisco, Seattle, Stanford, and Tampa, United StatesSee the 18 sites
Where in United States
- Northside HospitalAtlanta, United StatesNo longer taking part
- University of ColoradoAurora, United StatesNo longer taking part
- Dana-Farber Cancer InstituteBoston, United StatesNo longer taking part
- Massachusetts General HospitalBoston, United StatesNo longer taking part
- Roswell Park Comprehensive Cancer CenterBuffalo, United StatesNo longer taking part
- Levine Cancer InstituteCharlotte, United StatesNo longer taking part
- University of Chicago MedicineChicago, United StatesNo longer taking part
- Cleveland ClinicCleveland, United StatesNo longer taking part
- The Ohio State University Comprehensive Cancer CenterColumbus, United StatesNo longer taking part
- City of HopeDuarte, United StatesNo longer taking part
- University of MiamiMiami, United StatesNo longer taking part
- Vanderbilt University Medical CenterNashville, United StatesNo longer taking part
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesNo longer taking part
- New York - Presbyterian - Weill Cornell Medical CenterNew York, United StatesNo longer taking part
- University of California San FranciscoSan Francisco, United StatesNo longer taking part
- Fred Hutchinson Cancer CenterSeattle, United StatesNo longer taking part
- Stanford UniversityStanford, United StatesNo longer taking part
- H Lee Moffitt Cancer CenterTampa, United StatesNo longer taking part
Trial details
- Who runs it
- Center for International Blood and Marrow Transplant Research
- Trial code
- NCT05224661
- Record updated
- 1 June 2026
- Original description
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).Read full original descriptionShow less
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Inclusion: Provision of signed and dated informed consent form; Stated willingness to comply with all study procedures and availability for the duration of the study; Aged at least 18 years old at time of consent; Diagnosed with AML, in complete remission; Complete remission (CR) definition per local institutional criteria; CR with incomplete hematologic recovery (CRi) is not an exclusion criterion; MRD positivity is not an exclusion criterion; Undergoing alloHCT; Has a diagnostic AML specimen available.
Exclusion: Prior alloHCT; Diagnosis of acute promyelocytic leukemia.